Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Argininosuccinate synthetase 1 pseudogene 2 (ASS1P2) is classified as a pseudogene, meaning it is a DNA sequence similar to a known gene (argininosuccinate synthetase 1, or ASS1) but is not believed to encode a functional protein[5]. Pseudogenes arise through duplication or retrotransposition events, and typically do not produce active products due to mutations or lack of regulatory elements. Human genome annotations report multiple ASS1-related pseudogenes scattered throughout, with only the chromosome 9 copy (ASS1) encoding a functional enzyme; ASS1P2 is not among these functional genes[2][5]. Therefore, ASS1P2 is not considered a therapeutic target and does not play a known biological or disease role. If you intended to inquire about the functional enzyme argininosuccinate synthetase 1 (ASS1), that is a separate, well-studied gene involved in the urea cycle and disease (such as citrullinemia), in contrast to ASS1P2[1][2][3][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Argininosuccinate synthetase 1 pseudogene 2 (ASS1P2).